SMARCA4 and small cell lung carcinoma: Subsequently, we adopted second‐line treatment regimen for the following reasons: (1) to predict potential therapeutic targets based on genes; (2) neuroendocrine markers were significantly elevated (Figure 2); (3) in this case, the characteristics of SMARCA4‐UT are more inclined to small cell lung cancer.